MedicaidPrior AuthMedium impact
MAB2025110606
Pennsylvania Medicaid (DHS)·PA · Urology, Family Medicine, Internal Medicine·Provider Bulletin
Effective date
Jan 5, 2026
We identified it
Jun 20, 2026
Summary
Pennsylvania Medicaid is implementing new prior authorization requirements for Benign Prostatic Hyperplasia (BPH) treatments effective January 5, 2026. The policy updates medical necessity guidelines for non-preferred BPH medications, phosphodiesterase type 5 inhibitors, and situations involving therapeutic duplication or quantity limit overrides.
Action Required
Before January 5, 2026: Billing team must update prior authorization workflows for Pennsylvania Medicaid BPH treatment prescriptions. Ensure pharmacy staff understand new requirements for non-preferred BPH medications, phosphodiesterase type 5 inhibitors (like tadalafil), and therapeutic duplication scenarios. Update systems to flag prescriptions exceeding quantity limits. Train providers on documentation requirements including therapeutic failure history, contraindications, and appropriate dosing for medical necessity determinations.